ClinicalTrials.gg
CompletedNCT00812461ESENSE2Updated Jul 22, 2013Results posted

Efficacy of Nalmefene in Patients With Alcohol Dependence

A Phase 3 interventional study of Placebo and Nalmefene in Alcohol Dependence, sponsored by H. Lundbeck A/S. Completed at 57 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
678
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
Largest of 12
678 · median 212
Started
2009
with 1 other
Phase 3
6 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
5 of 12
H. Lundbeck A/S

Among the 12 studies testing nalmefene in Alcoholism, this one has the largest enrollment, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 3rd registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.

Read the detailed description

Alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. Excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. This study is planned to evaluate the efficacy and safety of as needed use of nalmefene 18.06 mg versus placebo in decreasing monthly Heavy Drinking Days (HDDs) and decreasing the total consumption during a period of 24 weeks in adult patients with alcohol dependence.

03

Conditions studied

  • Alcohol Dependence

Keywords

  • Pharmacologic Actions
  • Alcohol-Related Disorders
  • Alcoholism
  • Mental Disorders
  • Central Nervous System Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In- and outpatients who:

  • had a primary diagnosis of alcohol dependence according to - text revision (DSM-IV-TR) criteria
  • had had ≥6 HDDs in the 4 weeks preceding the Screening Visit
  • had had an average alcohol consumption at WHO medium risk level or above in the 4 weeks preceding the Screening Visit

Exclusion criteria

Exclusion Criteria:

The patient:

  • had a Axis I disorder other than alcohol dependence or nicotine dependence
  • had an antisocial personality disorder
  • had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)
  • had a history of delirium tremens or alcohol withdrawal seizures
  • reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists
  • reported current or recent treatment with antipsychotics or antidepressants
  • was pregnant or breast-feeding

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
678 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Nalmefene

    Drug: Nalmefene

Interventions

  • DrugPlacebo

    as-needed use, tablets, orally, 6 months

  • 18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.

    Also known as: Selincro™

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

    Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.

    Time frame: Baseline and Month 6

  2. Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

    TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Drinking Risk Level (RSDRL) Response

    RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

    Time frame: Month 6

  2. Change From Baseline in Clinical Status Using CGI-S

    The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 24

  3. Change in Clinical Status Using the CGI-I

    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 24

  4. Liver Function Test Gamma-glutamyl Transferase (GGT)

    GGT values

    Time frame: Week 24

  5. Liver Function Test Alanine Aminotransferase (ALAT)

    ALAT values

    Time frame: Week 24

07

Results

Posted Jul 9, 2013

Participant flow

All Randomised Patients
Participant flow — All Randomised Patients
MilestonePlaceboNalmefene 18.06 mg
Started360358
Completed337341
Not completed2317
Withdrew: Did not receive placebo/nalmefene2317
All Treated Patients
Participant flow — All Treated Patients
MilestonePlaceboNalmefene 18.06 mg
Started337341
Completed205194
Not completed132147
Withdrew: Adverse event815
Withdrew: Lack of efficacy137
Withdrew: Non-compliance69
Withdrew: Protocol violation3627
Withdrew: Withdrawal by subject4554
Withdrew: Lost to follow-up1114
Withdrew: Other reason1321

Outcome measures

PrimaryChange From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.

Time frame:
Baseline and Month 6
Reported as:
Mean · days
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
daysPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)-10.58 ± 0.52-12.30 ± 0.54
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Month 6 · p = 0.012 · Mean difference (final values): -1.72 · 95% CI -3.07 to -0.38The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 229 participants in the placebo group and 212 participants in the nalmefene group.
PrimaryChange From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).

Time frame:
Baseline and Month 6
Reported as:
Mean · g
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
gPlaceboNalmefene 18.06 mg
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)-54.06 ± 2.23-59.01 ± 2.29
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Month 6 · p = 0.088 · Mean difference (final values): -4.95 · 95% CI -10.63 to 0.73The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 229 participants in the placebo group and 212 participants in the nalmefene group.
SecondaryDrinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Drinking Risk Level (RSDRL) Response
percentage of participantsPlaceboNalmefene 18.06 mg
Drinking Risk Level (RSDRL) Response47.945.6
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted Odds Ratio (OR) response · p = 0.630 · Odds ratio (or): 0.92 · 95% CI 0.67 to 1.27
SecondaryChange From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Status Using CGI-S
units on a scalePlaceboNalmefene 18.06 mg
Change From Baseline in Clinical Status Using CGI-S-1.04 ± 0.08-1.27 ± 0.08
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 24 · p = 0.029 · Mean difference (final values): -0.23 · 95% CI -0.44 to -0.02The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 225 participants in the placebo group and 203 participants in the nalmefene group.
SecondaryChange in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Change in Clinical Status Using the CGI-I
units on a scalePlaceboNalmefene 18.06 mg
Change in Clinical Status Using the CGI-I2.68 ± 0.082.51 ± 0.08
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · Adjusted change from Baseline to Week 24 · p = 0.111 · Mean difference (final values): -0.17 · 95% CI -0.38 to 0.04The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 225 participants in the placebo group and 203 participants in the nalmefene group.
SecondaryLiver Function Test Gamma-glutamyl Transferase (GGT)

GGT values

Time frame:
Week 24
Reported as:
Geometric mean · IU/L
Liver Function Test Gamma-glutamyl Transferase (GGT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Gamma-glutamyl Transferase (GGT)44.9 ± 75.743.3 ± 75.2
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · [Adjusted values · p = 0.529 · Ratio to placebo: 0.96 · 95% CI 0.86 to 1.08The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 224 participants in the placebo group and 207 participants in the nalmefene group.
SecondaryLiver Function Test Alanine Aminotransferase (ALAT)

ALAT values

Time frame:
Week 24
Reported as:
Geometric mean · IU/L
Liver Function Test Alanine Aminotransferase (ALAT)
IU/LPlaceboNalmefene 18.06 mg
Liver Function Test Alanine Aminotransferase (ALAT)27.2 ± 56.325.0 ± 55.7
Statistical analysis
  • Placebo vs Nalmefene 18.06 mg · [Adjusted values · p = 0.049 · Ratio to placebo: 0.92 · 95% CI 0.84 to 1.00The Number of Participants Analyzed is participants with efficacy measurement available at this endpoint, that is, 222 participants in the placebo group and 205 participants in the nalmefene group.

Adverse events

Collected over Serious Adverse Events: 24 weeks, a 4-week run-out period, and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 24 weeks and a 4-week run-out period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—14/337 (4.2%)102/337 (30.3%)
Nalmefene 18.06 mg—7/341 (2.1%)157/341 (46%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboNalmefene 18.06 mg
Intentional overdoseInjury, poisoning and procedural complications3/3370/341
AlcoholismPsychiatric disorders0/3372/341
Pancreatitis acuteGastrointestinal disorders1/3370/341
Rectal haemorrhageGastrointestinal disorders1/3370/341
PneumoniaInfections and infestations1/3370/341
PyothoraxInfections and infestations1/3370/341
Subcutaneous abscessInfections and infestations1/3370/341
Accidental overdoseInjury, poisoning and procedural complications1/3370/341
Alcohol poisoningInjury, poisoning and procedural complications1/3370/341
Drug toxicityInjury, poisoning and procedural complications1/3370/341
Most frequent other events
Most frequent other events
EventPlaceboNalmefene 18.06 mg
NauseaGastrointestinal disorders20/33759/341
DizzinessNervous system disorders14/33752/341
InsomniaPsychiatric disorders23/33749/341
HeadacheNervous system disorders26/33743/341
NasopharyngitisInfections and infestations20/33722/341
VomitingGastrointestinal disorders8/33719/341
DiarrhoeaGastrointestinal disorders18/3378/341
AnxietyPsychiatric disorders17/33711/341

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboNalmefene 18.06 mgTotal
Mean44.4 ± 10.745.1 ± 10.744.8 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNalmefene 18.06 mgTotal
Female10492196
Male256266522
Previously Treated for Alcohol Dependence
Previously Treated for Alcohol Dependence(participants)PlaceboNalmefene 18.06 mgTotal
NO213215428
YES147142289
UNKNOWN011
Previously Treated for Alcohol Withdrawal Symptoms]
Previously Treated for Alcohol Withdrawal Symptoms](participants)PlaceboNalmefene 18.06 mgTotal
NO292300592
YES6857125
UNKNOWN011
Total Monthly Heavy Drinking Days (HDD)
Total Monthly Heavy Drinking Days (HDD)(days)PlaceboNalmefene 18.06 mgTotal
Mean18.37 ± 7.0319.71 ± 6.9619.04 ± 7.03
Total Alcohol Consumption (TAC) g Alcohol/Day
Total Alcohol Consumption (TAC) g Alcohol/Day(g)PlaceboNalmefene 18.06 mgTotal
Mean88.76 ± 48.1592.22 ± 46.8790.49 ± 47.52
Drinking Risk Level (DRL)
Drinking Risk Level (DRL)(participants)PlaceboNalmefene 18.06 mgTotal
Low6511
Medium8268150
High134129263
Very High138156294
Clinical Global Impression - Severity of Illness (CGI-S)
Clinical Global Impression - Severity of Illness (CGI-S)(units on a scale)PlaceboNalmefene 18.06 mgTotal
Mean3.99 ± 1.424.05 ± 1.454.02 ± 1.44

2 further baseline measures are reported on the registry.

08

Study locations

57 sites
  • BE002
    Assebroek, 8310, Belgium
  • BE007
    Brugge, 8000, Belgium
  • BE006
    Charleroi, 6000, Belgium
  • BE005
    Kortenberg, 3070, Belgium
  • BE001
    Liège, 4000, Belgium
  • BE003
    Mechelen, 2800, Belgium
  • BE004
    Oostende, 8400, Belgium
  • CZ001
    Litomerice, 41201, Czech Republic
  • CZ002
    Praha 10, 100 00, Czech Republic
  • CZ003
    Praha 6, 160 00, Czech Republic
  • FR008
    Angers, 4933, France
  • FR004
    Bully les Mines, 62160, France
  • FR009
    Clichy Cedex 92, 92110, France
  • FR012
    Elancourt, 78990, France
  • FR021
    La Rochelle, 17022, France
  • FR011
    Le Pecq, 78230, France
  • FR019
    Lille, 59037, France
  • FR016
    Lyon, 69005, France
  • FR014
    Nancy, 54000, France
  • FR015
    Nimes, 30029, France
  • FR002
    Rennes, 35000, France
  • FR001
    Sartrouville, 78500, France
  • FR007
    Strasbourg, 67000, France
  • FR005
    Toulouse, 31000, France
  • FR006
    Toulouse, 31200, France
  • FR003
    Villejuif, 94804, France
  • IT017
    Bologna, 40123, Italy
  • IT013
    Bologna, 44042, Italy
  • IT008
    Cento, 44042, Italy
  • IT006
    Firenze, 50134, Italy
  • IT002
    Parma, 43100, Italy
  • IT007
    Rome, 00123, Italy
  • IT001
    Rome, 00163, Italy
  • IT011
    Rome, RM 00168, Italy
  • IT004
    Rome, RM 00186, Italy
  • IT018
    Soverato, CZ 88068, Italy
  • PL005
    Gdansk, 80-952, Poland
  • PL004
    Leszno, 64-100, Poland
  • PL006
    Lublin, 20-109, Poland
  • PL007
    Lublin, 20-442, Poland
  • PL002
    Piekary Slaskie, 41940, Poland
  • PL003
    Skorzewo, 60-185, Poland
  • PL001
    Szczecin, 71-460, Poland
  • PT003
    Angra do Heroismo, 9700-161, Portugal
  • PT002
    Lisboa, 1350-179, Portugal
  • PT001
    Lisboa, 1649-035, Portugal
  • PT006
    Mem Martins, 2725, Portugal
  • ES005
    Alicante, 3550, Spain
  • ES006
    Barcelona, 8003, Spain
  • ES008
    Barcelona, 8025, Spain
  • ES004
    Barcelona, 8028, Spain
  • ES014
    Burgos, 9006, Spain
  • ES010
    Madrid, 28034, Spain
  • ES001
    Mallorca, 7193, Spain
  • ES002
    Oviedo, 33011, Spain
  • ES003
    Valencia, 46010, Spain
  • ES011
    Zamora, 49021, Spain
09

References and documents

Publications

  • Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3. PubMed 23562264 ↗
  • Aubin HJ, Reimer J, Nutt DJ, Bladstrom A, Torup L, Francois C, Chick J. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur Addict Res. 2015;21(3):160-168. doi: 10.1159/000371547. Epub 2015 Mar 31. PubMed 25832297 ↗
  • Laramee P, Brodtkorb TH, Rahhali N, Knight C, Barbosa C, Francois C, Toumi M, Daeppen JB, Rehm J. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014 Sep 16;4(9):e005376. doi: 10.1136/bmjopen-2014-005376. PubMed 25227627 ↗
  • van den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013 Sep-Oct;48(5):570-8. doi: 10.1093/alcalc/agt061. Epub 2013 Jul 19. Erratum In: Alcohol Alcohol. 2013 Nov-Dec;48(6):746. PubMed 23873853 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2008
First posted
Dec 22, 2008
Start
Mar 2009
Primary completionActual
Mar 2011
CompletionActual
Apr 2011
Results first posted
Jul 9, 2013
Last update
Jul 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00812461
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Mar 2009
Primary completion
Mar 2011
Completion
Apr 2011
Results posted
Jul 9, 2013
Last update
Jul 22, 2013

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion